Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.49% | 32.17% | 43.42% | 60.38% | 85.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.49% | 32.17% | 43.42% | 60.38% | 85.90% |
| Cost of Revenue | 32.14% | -112.51% | -8.50% | -5.75% | -1.35% |
| Gross Profit | 22.15% | 132.45% | 56.98% | 79.88% | 115.44% |
| SG&A Expenses | 32.93% | 66.02% | 90.17% | 114.47% | 134.23% |
| Depreciation & Amortization | 14.78% | 54.00% | 124.82% | 363.73% | 2,865.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.75% | 5.15% | 111.61% | 144.15% | 177.13% |
| Operating Income | 124.77% | 129.15% | -37.87% | -34.77% | -14.75% |
| Income Before Tax | 128.82% | 133.62% | -35.40% | -30.73% | -9.75% |
| Income Tax Expenses | 126.72% | 144.96% | -13.24% | -15.88% | 6.75% |
| Earnings from Continuing Operations | 129.50% | 130.18% | -41.02% | -34.49% | -14.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 129.50% | 130.18% | -41.02% | -34.49% | -14.05% |
| EBIT | 124.77% | 129.15% | -37.87% | -34.77% | -14.75% |
| EBITDA | 94.58% | 110.85% | -20.77% | -10.83% | 16.12% |
| EPS Basic | 104.98% | 110.06% | -47.03% | -37.90% | -16.13% |
| Normalized Basic EPS | 105.14% | 108.04% | -42.50% | -36.98% | -15.38% |
| EPS Diluted | 114.48% | 122.52% | -47.07% | -39.35% | -18.70% |
| Normalized Diluted EPS | 114.66% | 119.62% | -42.97% | -38.15% | -17.58% |
| Average Basic Shares Outstanding | 11.46% | 8.90% | 6.80% | 4.83% | 2.81% |
| Average Diluted Shares Outstanding | 11.55% | 8.81% | 3.36% | 1.92% | 0.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
